Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Cynthia Veenstra"'
Autor:
Martin Sjöström, Cynthia Veenstra, Erik Holmberg, Per Karlsson, Fredrika Killander, Per Malmström, Emma Niméus, Mårten Fernö, Olle Stål
Publikováno v:
Molecular Oncology, Vol 14, Iss 11, Pp 2713-2726 (2020)
Experimental studies suggest that hepatocyte growth factor (HGF) and its transmembrane tyrosine kinase receptor, Met, in part also relying on Akt kinase activity, mediate radioresistance. We investigated the importance of these biomarkers for the ris
Externí odkaz:
https://doaj.org/article/efd64e9c664e42559b7651d5419d26bc
Autor:
Cynthia Veenstra, Fredrika Killander, Mårten Fernö, Olle Stål, Per-Uno Malmström, Martin Sjöström, Per Karlsson, Emma Niméus, Erik Holmberg
Publikováno v:
Molecular Oncology, Vol 14, Iss 11, Pp 2713-2726 (2020)
Molecular Oncology
Molecular Oncology
We investigated the importance of HGF, pMET and pAkt for the risk of ipsilateral breast tumour recurrence after adjuvant radiotherapy in primary breast cancer in tumours from the SweBCG91‐RT randomised trial. Low levels of HGF and pMet in the tumou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b7fce98bc04dce9031a5a4ef66bb261
https://doi.org/10.1002/1878-0261.12803
https://doi.org/10.1002/1878-0261.12803
Autor:
Sanam Mirwani Mirwani, Olle Stål, Bo Nordenskjöld, Gizeh Pérez-Tenorio, Cynthia Veenstra, Tommy Fornander, Elin Karlsson
Publikováno v:
Journal of Cancer Research and Clinical Oncology
PurposeThe protein tyrosine phosphatase PTPN2 dephosphorylates several tyrosine kinases in cancer-related signalling pathways and is thought to be a tumour suppressor. As PTPN2 is not frequently studied in breast cancer, we aimed to explore the role
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::034637c6efb206c5fd1ff419b14bba91
http://europepmc.org/articles/PMC6571101
http://europepmc.org/articles/PMC6571101
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The protein tyrosine phosphatase, non-receptor type 2 (PTNP2) regulates receptor tyrosine kinase signalling, preventing downstream activation of intracellular pathways like the PI3K/Akt pathway. The gene encoding the protein is located on chr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::14f831959efed0587aa364a084ef0fb0
https://doi.org/10.1007/s00432-018-2810-6
https://doi.org/10.1007/s00432-018-2810-6
Autor:
Tommy Fornander, Sanam Mirwani Mirwani, Bo Nordensköljd, Elin Karlsson, Gizeh Pérez-Tenorio, Cynthia Veenstra, Olle Stål, Anna Stelling
Publikováno v:
Oncotarget
// Cynthia Veenstra 1 , Gizeh Perez-Tenorio 1 , Anna Stelling 1 , Elin Karlsson 1 , Sanam Mirwani Mirwani 1 , Bo Nordenskoljd 1 , Tommy Fornander 2 , Olle Stal 1 1 Department of Clinical and Experimental Medicine and Department of Oncology, Linkoping
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a69e8f5138af34c39ba0df95961b4fb3
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-130130
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-130130
Autor:
Cynthia Veenstra
Breast cancer is the most common form of cancer in women worldwide and the second leading cause of cancer death. It is a heterogeneous disease and is subdivided into different subtypes, all with different treatment responses and survival outcomes. Lu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e9e128e90969a873c1265e965f64e98
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-135047
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-135047
Autor:
Gizeh Pérez-Tenorio, Cynthia Veenstra, Elin Karlsson, Chhanda Dutta, Bo Nordenskjöld, Olle Stål, Tommy Fornander, Shad Emin
Breast cancer is a heterogeneous disease and new clinical markers are needed to individualise disease management and therapy further. Alterations in the PI3K/AKT pathway, mainly PIK3CA mutations, have been shown frequently especially in the luminal b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa23facd7c293258bd21bc2c1865f0a
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-121133
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-121133
Autor:
Anna-Lotta Hallbeck, Sander Ellegård, Olle Stål, Nils O. Elander, Cynthia Veenstra, Giseh Pérez-Tenorio
Publikováno v:
The Breast. 36:S46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ac46d51d9d5d8961fea50900d1cc0382
https://doi.org/10.1016/s0960-9776(17)30690-2
https://doi.org/10.1016/s0960-9776(17)30690-2
Autor:
Olle Stål, Bo Nordenskjöld, Tommy Fornander, Lambert Skoog, Cynthia Veenstra, Gizeh Pérez-Tenorio
Publikováno v:
Cancer Research. 73:427-427
The c-Met receptor promotes cell survival and proliferation by activating signalling pathways. c-Met is abundant in several cancers and in some cases it interferes with treatment response. In vitro, c-Met has been shown to be up-regulated and activat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ba61dd34ac6ff744e90e3f3e4c3a359
https://doi.org/10.1158/1538-7445.am2013-427
https://doi.org/10.1158/1538-7445.am2013-427
Publikováno v:
Clinical Cancer Research. 18:B59-B59
The hepatocyte growth factor receptor (HGFR), also known as the Met receptor, promotes cell survival and proliferation by activating signaling pathways such as the PI3K/Akt and RAS/MAPK pathway. HGFR, coded by MET, has been shown to be abundant in se
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3e2fd2d8b68d2a4b1c29e80de9261f83
https://doi.org/10.1158/1078-0432.mechres-b59
https://doi.org/10.1158/1078-0432.mechres-b59